Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adaptimmune Ther Ads (ADAP)

Adaptimmune Ther Ads (ADAP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Adaptimmune Reports Q2 Financial Results and Business Update

- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -

ADAP : 8.06 (-7.57%)
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative to the Company for ADP-A2M4...

ADAP : 8.06 (-7.57%)
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday,...

ADAP : 8.06 (-7.57%)
Growth Investing Leads in 1H: 5 Top ETFs & Stocks

Growth investing took a lead so far this year courtesy of massive money flowing into the economy.

NVAX : 167.50 (-3.45%)
NLS : 11.15 (-0.54%)
IWD : 119.12 (+0.16%)
ADAP : 8.06 (-7.57%)
IZEA : 1.7200 (-7.53%)
VUG : 224.18 (+1.14%)
JKE : 260.33 (+1.09%)
IWF : 213.37 (+0.93%)
MGK : 182.17 (+1.35%)
IWY : 119.04 (+1.35%)
VERI : 12.77 (+1.27%)
JKH : 320.23 (-0.63%)
Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Adaptimmune Therapeutics plc (ADAP).

ADAP : 8.06 (-7.57%)
How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong Industry

Adaptimmune Therapeutics (ADAP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

ADAP : 8.06 (-7.57%)
Worried About a Weak Dollar? Here's How to Trade & Win

The ultra-easy Fed policy and widening U.S. deficit are likely to keep the greenback subdued in this coming days.

AAPL : 455.61 (+3.49%)
BHP : 56.84 (+1.46%)
TXN : 133.74 (+0.78%)
PG : 132.71 (-0.55%)
YUM : 90.99 (-0.01%)
NEM : 70.11 (-0.37%)
FXE : 111.94 (+0.12%)
GMO : 0.2446 (-2.63%)
UUP : 25.08 (unch)
ADAP : 8.06 (-7.57%)
UDN : 21.20 (+0.09%)
TLND : 38.42 (+3.34%)
ADNT : 15.67 (-14.42%)
MYOV : 15.62 (-2.86%)
WPM : 55.40 (-1.44%)
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American...

ADAP : 8.06 (-7.57%)
Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?

Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.

ADAP : 8.06 (-7.57%)
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary...

ADAP : 8.06 (-7.57%)
Company News for June 1, 2020

Companies in the news are: ADAP, BIG, YAMHF, CGNX

BIG : 44.79 (-0.86%)
CGNX : 67.57 (-1.56%)
ADAP : 8.06 (-7.57%)
YAMHF : 15.9000 (+0.63%)
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares ("ADSs") in...

ADAP : 8.06 (-7.57%)
Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO.

ADAP : 8.06 (-7.57%)
AIM : 2.92 (-0.34%)
DVAX : 8.82 (-1.89%)
MEIP : 2.72 (-2.51%)
VIVO : 24.29 (-8.03%)
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers - Late Stage Development Initiated in EGJ Cancer

- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy -

ADAP : 8.06 (-7.57%)
Adaptimmune Reports Q1 Financial Results

- Upfront payment of $50m received from Astellas and approximately $90m offering completed -

ADAP : 8.06 (-7.57%)
Thinking about buying stock in Adaptimmune Therapeutics, Upwork, Eldorado Resorts, Co-Diagnostics, or Delta Air Lines?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, UPWK, ERI, CODX, and DAL.

ADAP : 8.06 (-7.57%)
DAL : 27.08 (+2.30%)
ERI : 38.24 (+0.63%)
UPWK : 13.92 (-7.75%)
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting

- Edited stem-cell derived T-cells can kill MAGE-A4 cancer targets in vitro -

ADAP : 8.06 (-7.57%)
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020

- The Company will also present updated data at three Congresses -

ADAP : 8.06 (-7.57%)
What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong Buy Stock

Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ADAP : 8.06 (-7.57%)
Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive...

ADAP : 8.06 (-7.57%)

Van Meerten Stock Picks

The 5 Best Large Caps
Today I wanted to find the 5 best Large Caps per my screening criteria.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar